Investor Bain Capital Life Sciences Opportunities III, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Bain Capital Life Sciences Opportunities III, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-14 13G/A CABA / Cabaletta Bio, Inc. 2,760,888 9,677,125
2025-02-14 13G/A IRON / Disc Medicine, Inc. 1,795,735 983,500
2024-11-14 13G/A IRON / Disc Medicine, Inc. 1,332,545 1,795,735
2024-08-22 13G CABA / Cabaletta Bio, Inc. 2,000,000 2,760,888
2024-04-25 13G IPSC / Century Therapeutics, Inc. 5,320,331
2024-02-14 13G KYTX / Kyverna Therapeutics, Inc. 3,163,868
2024-02-13 13G/A IRON / Disc Medicine, Inc. 1,990,914 1,332,545
2024-02-13 13G/A CARA / Cara Therapeutics, Inc. 2,696,030 0
2024-02-13 13G/A CABA / Cabaletta Bio, Inc. 2,000,000 2,000,000
2023-06-01 13G CABA / Cabaletta Bio, Inc. 2,000,000
2023-02-24 13G IRON / Disc Medicine, Inc. 1,990,914
2022-11-18 13G CARA / Cara Therapeutics, Inc. 2,696,030